Respiratory

Back to articles

Omadacycline: The latest option for community-acquired pneumonia

KEY POINT

Omadacycline (Nuzyra—Paratek) was shown to be noninferior to moxifloxacin for management of hospitalized adults with community-acquired bacterial pneumonia (CABP) for early clinical response, according to results of a study published in the New England Journal of Medicine.

SOURCES

Stets R, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517–27.

Chambers HF. Omadacycline — the newest tetracycline. N Engl J Med. 2019;380(6):588–9.